A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection for Subcutaneous Use in Healthy and Obese Subjects
Latest Information Update: 19 May 2025
At a glance
- Drugs ASC 47 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Gannex Pharma
Most Recent Events
- 11 May 2025 Treatment section is updated to remove the arms Experimental: Part I-SAD in healthy subjects (SAD Cohort 4, dose 4) and all the arms of PART 2.
- 11 May 2025 Status changed from recruiting to completed.
- 06 May 2025 According to Ascletis media release, The data from this study will be presented at the 32nd European Congress On Obesity (ECO 2025) in Malaga, Spain.